Study of LoVo Cells Resistant to Antitumor Agent FCE 24517
Author Information
Author(s): L. Capolongo, G. Melegaro, M. Broggini, N. Mongelli, M. Grandil
Primary Institution: Farmitalia Carlo Erba, Research Center, Oncology Department
Hypothesis
What are the resistance mechanisms of LoVo cells to the antitumor agent FCE 24517?
Conclusion
LoVo cells resistant to FCE 24517 show partial resistance mechanisms that are not solely mediated by mdr-1 overexpression.
Supporting Evidence
- LoVo/24517 cells showed a 56.3-fold resistance to FCE 24517.
- Resistance to FCE 24517 was only partially mediated by mdr-1 overexpression.
- LoVo/DX cells showed a 24-fold overexpression of mdr-1 mRNA.
Takeaway
Researchers studied cancer cells that became resistant to a new drug, FCE 24517, and found that they didn't resist it in the usual way that other drugs are resisted.
Methodology
The study involved isolating a resistant cell line and comparing its characteristics with a known resistant line, assessing drug resistance and mdr-1 mRNA expression.
Limitations
The study does not fully elucidate the mechanism of resistance and relies on specific cell lines.
Want to read the original?
Access the complete publication on the publisher's website